The Problem With Excluding Children From GLP-1 Trials In The U.S.

In this article, Dr. Evan Nadler brings urgent attention to a critical gap in obesity research: the exclusion of children from GLP-1 clinical trials in the United States. Drawing on his extensive clinical experience treating pediatric obesity, he explains why delaying access to new therapies puts millions of children at risk and argues for earlier inclusion of youth in drug development to better address this growing public health crisis.

Read the full article here.